Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06596473 · ClinicalTrials.gov registry record · Phase 1
A Study of BG-C477 in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 310
- Enrollment target
- 20
- Study locations
NCT06596473 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 310 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (57% higher). The trial reports 20 study locations across 18 states.
The verdict
NCT06596473, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 310 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.
Conditions Studied
Interventions
- DRUG Tislelizumab
- DRUG Chemotherapy
- DRUG BG-C477
Study Locations (20)
New South Wales
- Blacktown Cancer and Haematology Centre - Blacktown
- Northern Beaches Hospital - Frenchs Forest
Beijing Municipality
- Cancer Hospital Chinese Academy of Medical Sciences - Beijing
- Beijing Chest Hospital, Capital Medical University - Beijing
California
- City of Hope National Medical Center - Duarte
Connecticut
- Yale University, Yale Cancer Center - New Haven
Kansas
- The University of Kansas Cancer Center - Westwood
New Jersey
- John Theurer Cancer Center Hackensack University Medical Center - Hackensack
Texas
- The University of Texas Md Anderson Cancer Center - Houston
Queensland
- Sunshine Coast University Private Hospital - Birtinya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2024-10-03 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06596473
The ClinicalTrials.gov registry entry for NCT06596473 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (57% higher). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Tislelizumab is the first listed.
NCT06596473 reports 20 study locations spanning 18 distinct geographic areas - top geographies include New South Wales, Beijing Municipality, California.
Frequently Asked Questions
What is clinical trial NCT06596473 about?
NCT06596473 is a clinical study titled "A Study of BG-C477 in Participants With Advanced Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.
What is the current status of trial NCT06596473?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 310 participants. The study started on 2024-10-03. Estimated completion is 2027-12-31.
What conditions does trial NCT06596473 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06596473?
The interventions under investigation include: Tislelizumab (DRUG), Chemotherapy (DRUG), BG-C477 (DRUG).
Who is sponsoring clinical trial NCT06596473?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06596473 being conducted?
This trial has 20 study locations across California, Connecticut, Kansas, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.